Abstract
The enzymes that catalyze formation of the bioactive sphingolipid, sphingosine 1-phosphate, sphingosine kinase 1 and 2, are predictive markers in inflammatory diseases and cancer as evidenced by data from patients, knockout mice and the use of available molecular and chemical inhibitors. Thus, there is a compelling case for therapeutic targeting of sphingosine kinase. In addition, there are several examples of functional interaction between sphingosine 1-phosphate receptors and sphingosine kinase 1 that can drive malicious amplification loops that promote cancer cell growth. These novel aspects of sphingosine 1-phosphate pathobiology are reviewed herein.
Original language | English |
---|---|
Pages (from-to) | 121-129 |
Number of pages | 9 |
Journal | Advances in Biological Regulation |
Volume | 54 |
Early online date | 11 Sep 2013 |
DOIs | |
Publication status | Published - Jan 2014 |
Keywords
- sphingosine 1-phosphate
- cancer
- S1P
- cell growth
- inflammatory diseases
- sphingosine kinase